Xcout Intel
Congruence Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Congruence Therapeutics among biotechnology companies — ranked by similarity to what Congruence Therapeutics actually does, not by market-cap band.
Subscribe to see Congruence Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Congruence Therapeutics
Congruence Therapeutics is a clinical-stage biotechnology company located in Montreal, Quebec, that discovers and develops small molecule correctors and allosteric modulators for protein-misfolding diseases.
Congruence Therapeutics at a glance
Congruence Therapeutics is a biotechnology company headquartered in Canada. It has raised at least $115M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $65M in March 2023. Xcout tracks 21 named people at Congruence Therapeutics, including Clarissa Desjardins (CEO).
Congruence Therapeutics leadership
- Clarissa DesjardinsCEO
- Charles GrubsztajnCOO
- Frank TaffyCBO
- Michael D. HarveyCDO
- Sharath HegdeCSO
- Michael Rock GoldsmithChief Innovation Scientist
15 more named people on record for Congruence Therapeutics, with roles, board committees and tenure — see the full roster →
Congruence Therapeutics funding rounds
At least $115M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $65M | 3 named | |
| Series A | $50M | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Congruence Therapeutics competitors
Ranked by semantic similarity — how close each company is to Congruence Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
Biotech
Octant Bio is a biotechnology company that combines next-generation biology, chemistry, and computation to discover and develop precision small molecule therapeutics. The company targets complex cellular mechanisms to address genetic diseases, such as protein misfolding and mistrafficking across various therapeutic areas including genetic disorders, oncology, metabolism, and immunology.
Life Sciences
KisoJi Biotechnology Inc. is a drug discovery company headquartered in Montreal, Canada, utilizing a proprietary antibody discovery platform to create next-generation antibody drugs.
Biotech
Sharp Therapeutics Corp. is a preclinical-stage biotechnology and drug discovery company that develops small molecule therapies to treat genetic diseases and hereditary disorders. The company combines high-speed experimentation and computational methods to advance its drug discovery platform.
Similar biotechnology company
Cerevance is a pharmaceutical and biotechnology research company based in Boston, Massachusetts, that uses its proprietary NETSseq platform to develop cell-type specific treatments. The company focuses on neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders.
Biotech
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
Similar biotechnology company
Dewpoint Therapeutics is an integrated drug discovery platform company headquartered in Boston, Massachusetts. The firm leverages advanced biotechnology to translate condensate biology into novel medicines for various therapeutic areas.
Biotech
Aelin Therapeutics is a biopharmaceutical company based in Leuven, Belgium, that develops peptide-based novel drug modalities and biotherapeutic technology platforms designed to induce functional knockdown of target proteins through protein aggregation.
Similar biotechnology company
Neomorph is a clinical-stage biotechnology company founded in 2020 and headquartered in San Diego, California. The company pioneers the discovery and development of molecular glue degraders to target and destroy difficult disease-causing proteins.
Similar biotechnology company
Defence Therapeutics is a publicly traded Canadian biotechnology company headquartered in Montreal, Quebec. It is a precision intracellular drug-delivery company focused on unlocking the full potential of cancer biologics.
Biotech
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Similar biotechnology company
CHARM Therapeutics Inc. is a biopharmaceutical company utilizing proprietary technology platforms for drug discovery and therapeutic pipeline development.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Congruence Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Congruence Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →